Related Experiment Video
Updated: Aug 9, 2026
05:40
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
Published on: July 29, 2021
Migraine: current therapeutic targets and future avenues
D K Arulmozhi1, A Veeranjaneyulu, S L Bodhankar
1New Chemical Entity Research, Lupin Research Park, Village Nande, Taluk Mulshi, Pune, Maharashtra, India. adk_bits@yahoo.com
Current Vascular Pharmacology
|April 14, 2006
Summary
Migraine, a common headache disorder, involves vascular, neurological, and inflammatory factors. Current treatments offer limited efficacy, necessitating further research into its complex causes and improved therapies.
Area of Science:
- Neurology
- Pharmacology
- Pathophysiology
Background:
- Migraine is a prevalent neurological disorder affecting 10-20% of the global population, predominantly women.
- Characterized by severe headaches, often unilateral and throbbing, with or without aura.
- Pathophysiological theories include vascular changes, abnormal neurological activity, and neurogenic inflammation.
Purpose of the Study:
- To review the evidence linking migraine theories to its pathophysiology.
- To critically evaluate current therapeutic targets for acute and prophylactic migraine treatment.
- To explore future approaches for managing migraine.
Main Methods:
- Literature review of proposed migraine theories.
- Analysis of evidence connecting theories with pathophysiology.
- Critical evaluation of existing and potential migraine treatments.
Main Results:
- Current treatments, including 5-HT(1B/1D) receptor agonists for acute attacks and various agents for prophylaxis, show limitations in specificity and effectiveness.
- Despite research, the complex etiology of migraine remains incompletely understood.
- Migraine is often underdiagnosed, and available therapies are underutilized.
Conclusions:
- Further research is essential to elucidate the complex etiology of migraine.
- Improved diagnostic strategies and better utilization of existing therapies are needed.
- Development of more targeted and effective acute and prophylactic treatments is a priority.
Related Concept Videos
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...
01:26Cholinergic Antagonists: Therapeutic Uses
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...